- OptraSCAN ® Unveils OS-Ultra 320 First Ever High-Speed Scanner At Economical Pricing
- Unparalleled Image Quality Within Seconds
SAN JOSE, Calif- OptraSCAN®, the leading end-to-end digital pathology solution provider, announced the launch of OS-Ultra 320 the world’s first-ever affordable high-speed digital pathology scanner. The OS-Ultra 320 scans tissues/cells of size 15x15 mm area at 40x magnification in less than 60 seconds and features no-touch continuous loading operation. The OS-Ultra 320 is designed to reduce workflow errors and scale-up pathology laboratory operations.
“We are disrupting digital transformation of Pathology and Cytology through affordability,” said Abhi Gholap, Founder of OptraSCAN. “With our 15-slide scanner getting tremendous traction for small laboratories, we are happy to launch our high performance 320 slide scanning device at an economical pricing as a complete solution to scan-store-analyze-share the cases,” he further added.
“OS-Ultra 320 represents a significant development in reducing technician time while maintaining perfect image quality for the healthcare professionals. It will provide better performance and improved capabilities,” said Dr. Clive Taylor, Chief Medical Officer of OptraSCAN.
OS-Ultra Technical Specifications:
• Continuous Slide Loading: Intuitive interface with fully automated walk-away acquisition
• Light Source: LED
• Focusing Technique: Real-Time Auto Focus
• File Format: JPEG2000, TIFF ability to convert file formats
• Slide Formats: Standard 25x75mm (1"x3") slides, 50x75mm (2"x3") slides
• Slide Tolerances: Length: ± 1mm, Width: ± 1mm, Thickness ± 0.2mm
• Resolution: 0.25 μ /pixel
• Workflow Software application
• TELEPath application
• Image Analysis Suite for Breast, Prostate, Brain, Renal and Lung (IHC and H&E)
OS-Ultra is also available for purchase via our partners Nikon USA, FujiFilm and our other distributors - https://www.optrascan.com/contact-us
For scheduling demo, please get in touch at ultra@optrascan.com
About OptraSCAN, Inc:
OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to "Go Digital" no matter the size of the pathology lab, the lab’s throughput or global location.
OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model. Follow Us on LinkedIn and Twitter.
Contacts:
Anjana Athanikar | Manager – Marketing Communications | 91.20.66540900 x 231 | a.athanikar@optraventures.com
(Added: Fri Apr 02 2021 Hits: 10 Rating: 0.00 Votes: 0) Rate It
- Professional medical service provider for ultrasound
- As one of the leading third-party service companies in China, Rongtao Medical provides healthcare solutions, repair service, parts and accessories to hospitals, clinics and distributors world-widely.
Following are the main projects we based on:
Repair Ultrasound (Ultrasound Board/ASSY Repair, Probe Repair)
Repair Associated Items (Endoscopy Repair, Patient Monitor Repair, Ventilator Repair)
Parts & Accessories (Compatible/Original Ultrasound Transducer, Ultrasound Biopsy Needle Guide, Patient Monitor Module,CT part)
To support top quality repair service and most reasonable price, we have the below well-armed teams to deal with each and every service chain.
★Professional & passionate pre-sale service team
★10 years experienced repair technician team
★Reliable & responsible quality control team
★Experienced & specialize after-sale technical support team
Besides technical service, we have wide range of ultrasound parts/accessories, ultrasound probes, patient monitor parts, patient monitor models readily available for sale, not only to serve our customer with the best quality repairs, but the cost-effective sales.
Our Vision --- To be the top preferred third-party service company worldwide !
If you are looking for any related repair service or parts, please don’t hesitate to contact us, we are always here to help!
(Added: Fri Apr 02 2021 Hits: 9 Rating: 0.00 Votes: 0) Rate It
- 10th International Conference on Stroke and Cerebrovascular Diseases
- "On behalf of the Organizing Committee, it is with great pleasure that we welcome you to the official website of the10th International Conference on Stroke and Cerebrovascular Diseases schedule for June 28-29, 2021 in Paris, France.
STROKE CONGRESS 2021 aims to bring leading academic scientists, researchers, and research scholars together to exchange and share their experiences and research results about all aspects of Neurological Disorders. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Neuroscience.
The highlights of the STROKE CONGRESS 2021 are Neurons and Neurology, Neuroscience, Stroke and Neurological disorders, Dementia, Mental Health: Alzheimers disease, Neuro-Pharmacology, Parkinsons disease, Huntingtons Disease, Neuromuscular and Neurocognitive Disorders, Cerebrovascular Disease, Neurodegenerative Disorders, CNS Disorders, Stroke Management, Stroke Rehabilitation and Recovery, Neuropsychiatry and Psychology, Neuro-Oncology, Brain tumour, Risk Assessment and Prevention of Stroke, Seizure Disorders and Epilepsy, Neuro Diagnosis Imaging techniques, Neurological disorders: Research and Treatments, Therapeutics Approaches for Neurological Disorders"
(Added: Thu Apr 01 2021 Hits: 6 Rating: 0.00 Votes: 0) Rate It
- NeurOptics Launches Pupillometry Program at Vanderbilt University Medical Center
- IRVINE, Calif.—April 01, 2021—NeurOptics, the leader in the science of pupillometry, recently announced that its NPi®-200 pupillometers and the Neurological Pupil Index™ (NPi®) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, a highly acclaimed teaching hospital in Nashville, Tenn., as an important measurement for managing patients with brain injury.
Vanderbilt’s 24-bed Neuro ICU implemented 12 of NeurOptics’ NPi®-200 pupillometers, or one pupillometer per nurse. As a comprehensive stroke center, Vanderbilt has one of the largest Neuro ICUs in the country, treating patients from all over the southeastern region of the United States. Pupillometry and NPi will provide nurses and clinicians with an accurate, reliable, and objective measurement of pupil size and reactivity to support the assessment of neurological examinations in patients with brain injury across a broad spectrum of diagnoses, including traumatic brain injury, stroke and patients with other primary diagnoses at risk of secondary neurological injury.
“We are proud to support Vanderbilt University Medical Center as it implements pupillometry in its award-winning Neuro ICU,” said Kathleen Pierson, Vice President, Global Sales and Marketing. “Pupillometry using NeurOptics' NPi will allow the Neuro ICU team to objectively and accurately track changes in the pupillary light reflex over time, helping to inform treatment decisions for patients with brain injury. Adding Vanderbilt to the more than 480 hospitals across the U.S. that have adopted NeurOptics’ pupillometers strengthens our continued drive to create innovative technology that may help inform medical decision making and improve patient outcomes."
Automated infrared pupillometry is an objective assessment of the pupillary light reflex that is measured using NeurOptics’ NPi-200 Pupillometer. The NPi-200 Pupillometer measures pupil size and reactivity, expressed as the Neurological Pupil index (NPi). NPi values range from 0 to 4.9, with scores under 3 considered abnormal. The pupillometer eliminates the variability and subjectivity inherent in manual pupillary evaluation, providing more accurate, reliable, and objective pupil size and reactivity measurement for this vital component of neurological examinations in patients with the potential for brain injury.
About NeurOptics
Headquartered in Irvine, Calif., NeurOptics is the leader in the science of pupillometry. Driven by a passion to help clinicians improve patient outcomes, NeurOptics develops and markets innovative technology for use in critical care medicine, neurology, neurosurgery, emergency medicine, and research. The NeurOptics NPi-200 Pupillometer has been included in more than 70 clinical studies, adopted in over 480 hospitals in the United States, and is represented in more than 26 countries worldwide. For more information, visit www.NeurOptics.com. Follow NeurOptics on Facebook, LinkedIn, and Twitter @NeurOpticsInc.
Media Contact
Andrea Sampson, Sampson PR Group
562/304-0301, asampson@sampsonprgroup.com
(Added: Thu Apr 01 2021 Hits: 6 Rating: 0.00 Votes: 0) Rate It
- 12th European Conference on "Surgery and Cosmetology"
- In light of your renowned research and expertise, we are pleased to welcome you all as our Honorable Speaker for the 12th European Conference on "Surgery and Cosmetology" to be seized on May 10-11, 2021, ONLINE.
This conference aims to bring together leading Doctors, Academic Scientists, Researchers, Students and major companies to share their experiences and research results in their on-going project in different forms of Surgery and Cosmetology. We consider this a fantastic occasion to attend this conference along with your research member(s), with a view to conduct an exclusive session to discuss the novel technologies and innovative methods in your area of expertise.
In addition to Speeches, Posters presentations, Workshops, Exhibitions and Discussions, the conference also offers an unparalleled time for renewing professional relationships, for networking and for keeping up-to-date with variations in your challenging and expanding research work. Euro Surgery 2021 provides a platform of international standards where you can discuss and influence regarding key advances in Surgery.
(Added: Wed Mar 31 2021 Hits: 5 Rating: 0.00 Votes: 0) Rate It
- 12th European Conference on "Surgery and Cosmetology"
- In light of your renowned research and expertise, we are pleased to welcome you all as our Honorable Speaker for the 12th European Conference on "Surgery and Cosmetology" to be seized on May 10-11, 2021, ONLINE.
This conference aims to bring together leading Doctors, Academic Scientists, Researchers, Students and major companies to share their experiences and research results in their on-going project in different forms of Surgery and Cosmetology. We consider this a fantastic occasion to attend this conference along with your research member(s), with a view to conduct an exclusive session to discuss the novel technologies and innovative methods in your area of expertise.
In addition to Speeches, Posters presentations, Workshops, Exhibitions and Discussions, the conference also offers an unparalleled time for renewing professional relationships, for networking and for keeping up-to-date with variations in your challenging and expanding research work. Euro Surgery 2021 provides a platform of international standards where you can discuss and influence regarding key advances in Surgery.
(Added: Wed Mar 31 2021 Hits: 8 Rating: 0.00 Votes: 0) Rate It
- 12th European Conference on "Surgery and Cosmetology"
- In light of your renowned research and expertise, we are pleased to welcome you all as our Honorable Speaker for the 12th European Conference on "Surgery and Cosmetology" to be seized on May 10-11, 2021, ONLINE.
This conference aims to bring together leading Doctors, Academic Scientists, Researchers, Students and major companies to share their experiences and research results in their on-going project in different forms of Surgery and Cosmetology. We consider this a fantastic occasion to attend this conference along with your research member(s), with a view to conduct an exclusive session to discuss the novel technologies and innovative methods in your area of expertise.
In addition to Speeches, Posters presentations, Workshops, Exhibitions and Discussions, the conference also offers an unparalleled time for renewing professional relationships, for networking and for keeping up-to-date with variations in your challenging and expanding research work. Euro Surgery 2021 provides a platform of international standards where you can discuss and influence regarding key advances in Surgery.
(Added: Wed Mar 31 2021 Hits: 12 Rating: 0.00 Votes: 0) Rate It
- 12th European Conference on "Surgery and Cosmetology"
- In light of your renowned research and expertise, we are pleased to welcome you all as our Honorable Speaker for the 12th European Conference on "Surgery and Cosmetology" to be seized on May 10-11, 2021, ONLINE.
This conference aims to bring together leading Doctors, Academic Scientists, Researchers, Students and major companies to share their experiences and research results in their on-going project in different forms of Surgery and Cosmetology. We consider this a fantastic occasion to attend this conference along with your research member(s), with a view to conduct an exclusive session to discuss the novel technologies and innovative methods in your area of expertise.
In addition to Speeches, Posters presentations, Workshops, Exhibitions and Discussions, the conference also offers an unparalleled time for renewing professional relationships, for networking and for keeping up-to-date with variations in your challenging and expanding research work. Euro Surgery 2021 provides a platform of international standards where you can discuss and influence regarding key advances in Surgery.
(Added: Wed Mar 31 2021 Hits: 7 Rating: 0.00 Votes: 0) Rate It
- International Conference on Animal Health
- We would like to spread the will to influence everyone around the globe regarding the protection of animals which simultaneously reflects the global atmosphere of the earth. With absolute eagerness & enthusiasm we like to extend a warm welcome to join the most awaited gathering in the field of Animal Health & Veterinary Medicine slated on November 22-23, 2021 in the most beautiful city of Dubai, UAE.
Unique theme for this year’s 2 days gathering is Embellish the unexplored inventions in the field of Animal health.
Animal Health 2021 will be one of your best opportunities to meet the attendees from all over the globe. Come to Participate, mingle and exchange your innovative information’s with the most potential scientists, professionals & doctors to gain more knowledge in the field of Animal Health through creating a powerful impact on the need for realization & development of the amity between the humans & animals through recognition from the honourable organizing committee of this event.
Join us at Animal Health 2021 with a unique presentation on the tracks Animal Breeding, Animal Forensics, Animal Diseases, Veterinary Chiropractic, Veterinary Dentistry, Veterinary Ophthalmology, Veterinary Oncology, Animal Toxicology, Animal Welfare, Dairy farming technology, Animal genetics, Veterinary Vaccines, Veterinary Research, Pet First Aid, Poultry farming & many more.
Who can attend the conference?
Animal Health 2021 will provide an adorable platform to Veterinarians, Veterinary Technicians, Veterinary Clinic Teams, Researchers and Specialists, Veterinary Faculty, Veterinary Medicine Faculty, Animal Sciences Faculty, Veterinary Students, Animal Science Students, Veterinary Nurse, Veterinary Groups, Animal Health Companies, Veterinary societies & Associations etc.
Benefits of attending Animal Health 2021:
Establish yourself as Animal Health expert
Promote your research ideas in International platform
Gather vision about the recent innovations in the field of Animal Health
To get recognized in a global platform and discuss research ideas with the eminent medical experts
Good opportunity to Advertisers at this vicious gathering
(Added: Wed Mar 31 2021 Hits: 9 Rating: 0.00 Votes: 0) Rate It
- International Conference on Animal Health
- We would like to spread the will to influence everyone around the globe regarding the protection of animals which simultaneously reflects the global atmosphere of the earth. With absolute eagerness & enthusiasm we like to extend a warm welcome to join the most awaited gathering in the field of Animal Health & Veterinary Medicine slated on November 22-23, 2021 in the most beautiful city of Dubai, UAE.
Unique theme for this year’s 2 days gathering is Embellish the unexplored inventions in the field of Animal health.
Animal Health 2021 will be one of your best opportunities to meet the attendees from all over the globe. Come to Participate, mingle and exchange your innovative information’s with the most potential scientists, professionals & doctors to gain more knowledge in the field of Animal Health through creating a powerful impact on the need for realization & development of the amity between the humans & animals through recognition from the honourable organizing committee of this event.
Join us at Animal Health 2021 with a unique presentation on the tracks Animal Breeding, Animal Forensics, Animal Diseases, Veterinary Chiropractic, Veterinary Dentistry, Veterinary Ophthalmology, Veterinary Oncology, Animal Toxicology, Animal Welfare, Dairy farming technology, Animal genetics, Veterinary Vaccines, Veterinary Research, Pet First Aid, Poultry farming & many more.
Who can attend the conference?
Animal Health 2021 will provide an adorable platform to Veterinarians, Veterinary Technicians, Veterinary Clinic Teams, Researchers and Specialists, Veterinary Faculty, Veterinary Medicine Faculty, Animal Sciences Faculty, Veterinary Students, Animal Science Students, Veterinary Nurse, Veterinary Groups, Animal Health Companies, Veterinary societies & Associations etc.
Benefits of attending Animal Health 2021:
Establish yourself as Animal Health expert
Promote your research ideas in International platform
Gather vision about the recent innovations in the field of Animal Health
To get recognized in a global platform and discuss research ideas with the eminent medical experts
Good opportunity to Advertisers at this vicious gathering
(Added: Wed Mar 31 2021 Hits: 9 Rating: 0.00 Votes: 0) Rate It
- International Conference on Animal Health
- We would like to spread the will to influence everyone around the globe regarding the protection of animals which simultaneously reflects the global atmosphere of the earth. With absolute eagerness & enthusiasm we like to extend a warm welcome to join the most awaited gathering in the field of Animal Health & Veterinary Medicine slated on November 22-23, 2021 in the most beautiful city of Dubai, UAE.
Unique theme for this year’s 2 days gathering is Embellish the unexplored inventions in the field of Animal health.
Animal Health 2021 will be one of your best opportunities to meet the attendees from all over the globe. Come to Participate, mingle and exchange your innovative information’s with the most potential scientists, professionals & doctors to gain more knowledge in the field of Animal Health through creating a powerful impact on the need for realization & development of the amity between the humans & animals through recognition from the honourable organizing committee of this event.
Join us at Animal Health 2021 with a unique presentation on the tracks Animal Breeding, Animal Forensics, Animal Diseases, Veterinary Chiropractic, Veterinary Dentistry, Veterinary Ophthalmology, Veterinary Oncology, Animal Toxicology, Animal Welfare, Dairy farming technology, Animal genetics, Veterinary Vaccines, Veterinary Research, Pet First Aid, Poultry farming & many more.
Who can attend the conference?
Animal Health 2021 will provide an adorable platform to Veterinarians, Veterinary Technicians, Veterinary Clinic Teams, Researchers and Specialists, Veterinary Faculty, Veterinary Medicine Faculty, Animal Sciences Faculty, Veterinary Students, Animal Science Students, Veterinary Nurse, Veterinary Groups, Animal Health Companies, Veterinary societies & Associations etc.
Benefits of attending Animal Health 2021:
Establish yourself as Animal Health expert
Promote your research ideas in International platform
Gather vision about the recent innovations in the field of Animal Health
To get recognized in a global platform and discuss research ideas with the eminent medical experts
Good opportunity to Advertisers at this vicious gathering
(Added: Wed Mar 31 2021 Hits: 14 Rating: 0.00 Votes: 0) Rate It
- wearable injectors market is estimated to be worth around USD 600 million- "Roots Analysis"
- Roots Analysis is pleased to announce the publication of its recent study, titled, “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely future evolution of these self-injection devices over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed review of the overall landscape of large volume wearable injectors available for delivery of insulin and non-insulin drugs, in addition to the under development / available drug device combinations
An insightful competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power and product specifications
Elaborate profiles of the prominent companies that develop large volume wearable injectors.
An analysis of the partnerships that have been established in the period between 2015 and 2020.
A detailed analysis on acquisition targets.
An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors over the last three decades.
A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future
A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors on Twitter
A detailed analysis of completed, ongoing and planned clinical trials
A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain
An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval, in general.
A detailed market forecast, featuring analysis of the financial opportunity within the large volume wearable injectors market (for delivery of non-insulin and insulin drugs) across the following segments:
Type of Device
Patch Pump / Injectors
Infusion Pump / Injectors
Product Usability
Disposable
Re-usable
Therapeutics Area (for non-insulin drugs)
Neurological Disorders
Cardiovascular Disorders
Oncological Disorders
Infectious Disorders
Key Geographical Regions
North America
Europe
Asia-Pacific
Key companies covered in the report:
Becton Dickinson
Bespak (subsidiary of Consort Medical)
CeQur
Debiotech
Eli Lilly
Enable Injections
Insulet
Medtronic
PharmaSens
Roche
SOOIL Development
Sonceboz
Sensile Medical (acquired by Gerresheimer)
SteadyMed Therapeutics (acquired by United Therapeutics)
Tandem Diabetes Care
Weibel CDS (acquired by SHL Medical)
West Pharmaceutical Services
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html
Other recent offerings:
1. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030 [COVID-19 Series]
2. Global Autoinjectors Market (3rd Edition), 2020-2030
3. Prefilled Syringes Market (5th Edition), 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
(Added: Wed Mar 31 2021 Hits: 8 Rating: 0.00 Votes: 0) Rate It
- Webinar On Gastroenterology
- Meetings International welcomes you to attend the Webinar on Gastroenterology scheduled on April 28, 2021
Gastroenterology 2021 "Understanding Gastroenterology through a Multidisciplinary Approach” aims to compile leading academic scientists, researchers, and research scholars to exchange and share their experiences and research results on all aspects of Gastroenterology.
(Added: Wed Mar 31 2021 Hits: 7 Rating: 0.00 Votes: 0) Rate It
- International Conference on Gastroenterology
- With the amalgamation of peerless speakers of Gastroenterology 2021, we are privileged to announce International Conference on Gastroenterology is scheduled during December 01-02 at Dubai | UAE.
The scientific program of Gastroenterology 2021 "Understanding Gastroenterology through a Multidisciplinary Approach” includes a wide range of Keynote presentations, Plenary talks, Video presentations, Symposia, Workshops, Exhibitions, Poster presentations, and e-posters.
(Added: Wed Mar 31 2021 Hits: 13 Rating: 0.00 Votes: 0) Rate It
- Introducing: Laser Hair Removal at Mane Center for Advanced Hair Restoration
- Mane Center for Advanced Hair Restoration, located in Chevy Chase, Maryland, is incredibly pleased to announce that we are now offering the latest laser hair removal treatment near you.
Mane Center’s laser hair removal is a non-invasive and safe procedure that uses high-intensity laser beams to prevent hair growth, by damaging the hair follicles. With the acquisition of the Venus Epileve hair removal device we now offer state-of-the-art laser technology. This procedure can effectively remove hair from nearly any part of the body, including the face, neck, arms, chest, shoulders, underarms, legs, back, and bikini lines.
Laser hair removal is usually permanent, but requires occasional touchup sessions after your treatment to maintain the results. This is a medical procedure that requires trained professionals to perform. Mane Center for Advanced Hair Restoration has a dedicated team of qualified medical professionals performing this procedure. Our laser hair removal price starts at $50, but varies depending on the size of the treatment area and the number of sessions required.
Benefits of Laser Hair Removal:
Accurate results with no downtime
Treatment requires only a few minutes to an hour
Provides permanent results after 3 to 7 sessions
Eliminates ingrown hairs
The perfect option for people with sensitive skin
(Added: Wed Mar 31 2021 Hits: 6 Rating: 0.00 Votes: 0) Rate It
- Yoga Teacher Training in Rishikesh India
- Yoga Teacher Training in Rishikesh India
yoga Teacher Training in India
Yoga Teacher Training in Rishikesh at Arogya Yoga School, Rishikesh. Certified by Yoga Alliance USA, Yoga Teacher Training Coursein Rishikesh, India as confident teachers with a strong and solid teaching skill set ready to begin their career in the world of Yoga.
Yoga Teacher Training in India at Arogya Yoga School as confident teachers with strong and solid teaching skills, ready to start their career in yoga. They develop a unique art of teaching along with a comprehensive understanding of asana, pranayama, shatkarma, alignment, Ayurveda, philosophy, anatomy, mudras, mantras and meditation. Our Yoga Alliance registered Yoga Teacher Training in India is intensive and enriching for yoga beginners to intermediates. With over 1000 graduates and a decade of teaching experience, our established Yoga Teacher Training in India Program fulfils the best and highest standards for aspiring Yoga Teachers.
Alongside developing practical skills in the art of teaching, our trainees also gain a comprehensive understanding of: Best Yoga Teacher Training in Rishikesh India
Yoga Teacher Training Rishikesh
Yoga Teacher Training in Rishikesh syllabus
– Yoga Asana
– Yoga Asana Adjustments
– Philosophy
– Physiology
– Mantra Chanting
– Chakras
– Anatomy
– Ayurveda
– Mudras
– Pranayama
– Meditation
Yoga Teacher Training Curriculum :
Mantra Chanting.
Cleansing techniques (Shat karma).
Study of asana: proper alignment, variations, modifications with ability to minimize the risk of injuries and Hands-on adjustments.
Art of sequencing and improvisation in the class.
Intelligent use of props to help improve practice at its early stages.
Postures with their Sanskrit Names and terminology.
Technique and practice of breathing (Pranayama).
Meditation (Dhyana).
Fundamentals of human anatomy and physiology.
Yoga Philosophy, Ideas and Hypothesis
Confidence-building through teaching-practice
Yoga Teacher Training in Rishikesh: Daily Schedule
6:00 AM - 7:30 AM, Yoga
7:45 AM - 8:45 AM, Pranayama
9:00 AM - 10:00 AM, Breakfast
10:30 AM - 11:30 AM, Yoga Philosophy
11:30 AM - 12:00 PM, Break
12:00 PM - 1:00 PM, Teaching methodology
1:00 PM - 1:45 PM, Lunch
3:00 PM - 4:00 PM, Yoga Anatomy/Alignment Class
4:00 PM - 4:15 PM, Tea Break
4:15 PM - 5:45 PM, Yoga
6:00 PM - 7:00 PM, Meditation/Yoga Nidra
Best Yoga Teacher Training in Rishikesh India - Affiliation With Yoga Alliance
200 Hour Yoga Teacher Training Course in Rishikesh, India, at Arogya yoga School is affiliated with Yoga Alliance accreditation. After the culmination of the course, participants will be awarded a 200 RYT certificate which makes them qualified to teach yoga across the globe as well as get enlisted with Yoga Alliance USA.
Yoga Alliance certified Yoga Teacher Training in Rishikesh, India
WHAT DOES THE COURSE FEES INCLUDE ?
» 28 nights Single Accommodation
» Daily nutritious vegetarian meals and teas
» Weekend excursions
» Course materials will be provided (books, yoga mat, cleansing kit)
WHAT NOT INCLUDE ?
Air fare
Air condition on additional cost
Arogya Yoga School Yoga Teacher Training Course:
(Added: Tue Mar 30 2021 Hits: 11 Rating: 0.00 Votes: 0) Rate It
- Yoga Teacher Training in Rishikesh India
- Yoga Teacher Training in Rishikesh India
yoga Teacher Training in India
Yoga Teacher Training in Rishikesh at Arogya Yoga School, Rishikesh. Certified by Yoga Alliance USA, Yoga Teacher Training Coursein Rishikesh, India as confident teachers with a strong and solid teaching skill set ready to begin their career in the world of Yoga.
Yoga Teacher Training in India at Arogya Yoga School as confident teachers with strong and solid teaching skills, ready to start their career in yoga. They develop a unique art of teaching along with a comprehensive understanding of asana, pranayama, shatkarma, alignment, Ayurveda, philosophy, anatomy, mudras, mantras and meditation. Our Yoga Alliance registered Yoga Teacher Training in India is intensive and enriching for yoga beginners to intermediates. With over 1000 graduates and a decade of teaching experience, our established Yoga Teacher Training in India Program fulfils the best and highest standards for aspiring Yoga Teachers.
Alongside developing practical skills in the art of teaching, our trainees also gain a comprehensive understanding of: Best Yoga Teacher Training in Rishikesh India
Yoga Teacher Training Rishikesh
Yoga Teacher Training in Rishikesh syllabus
– Yoga Asana
– Yoga Asana Adjustments
– Philosophy
– Physiology
– Mantra Chanting
– Chakras
– Anatomy
– Ayurveda
– Mudras
– Pranayama
– Meditation
Yoga Teacher Training Curriculum :
Mantra Chanting.
Cleansing techniques (Shat karma).
Study of asana: proper alignment, variations, modifications with ability to minimize the risk of injuries and Hands-on adjustments.
Art of sequencing and improvisation in the class.
Intelligent use of props to help improve practice at its early stages.
Postures with their Sanskrit Names and terminology.
Technique and practice of breathing (Pranayama).
Meditation (Dhyana).
Fundamentals of human anatomy and physiology.
Yoga Philosophy, Ideas and Hypothesis
Confidence-building through teaching-practice
Yoga Teacher Training in Rishikesh: Daily Schedule
6:00 AM - 7:30 AM, Yoga
7:45 AM - 8:45 AM, Pranayama
9:00 AM - 10:00 AM, Breakfast
10:30 AM - 11:30 AM, Yoga Philosophy
11:30 AM - 12:00 PM, Break
12:00 PM - 1:00 PM, Teaching methodology
1:00 PM - 1:45 PM, Lunch
3:00 PM - 4:00 PM, Yoga Anatomy/Alignment Class
4:00 PM - 4:15 PM, Tea Break
4:15 PM - 5:45 PM, Yoga
6:00 PM - 7:00 PM, Meditation/Yoga Nidra
Best Yoga Teacher Training in Rishikesh India - Affiliation With Yoga Alliance
200 Hour Yoga Teacher Training Course in Rishikesh, India, at Arogya yoga School is affiliated with Yoga Alliance accreditation. After the culmination of the course, participants will be awarded a 200 RYT certificate which makes them qualified to teach yoga across the globe as well as get enlisted with Yoga Alliance USA.
Yoga Alliance certified Yoga Teacher Training in Rishikesh, India
WHAT DOES THE COURSE FEES INCLUDE ?
» 28 nights Single Accommodation
» Daily nutritious vegetarian meals and teas
» Weekend excursions
» Course materials will be provided (books, yoga mat, cleansing kit)
WHAT NOT INCLUDE ?
Air fare
Air condition on additional cost
Arogya Yoga School Yoga Teacher Training Course:
(Added: Tue Mar 30 2021 Hits: 4 Rating: 0.00 Votes: 0) Rate It
- BAJAJ EYE CENTER DELHI IS AVAILABLE FOR AN EYE SURGERY WITH BLADELESS AND PAINLESS PROCEDURE
- Smile eye surgery in Delhi is currently available at the Bajaj eye Center. SMILE Lasik procedure is the most advanced eye surgery for clear vision/enhancing vision. SMILE procedure is better than any eye surgery procedure because it is less invasive than the LASIK procedure. It only takes 2-4 hours of recovery time to return to normal activity. SMILE surgery at Bajaj Eye Center is the third-generation ocular surgery for astigmatism and myopia with many benefits. People with eyesight problems could undergo Smile Lasik in Delhi at Bajaj Eye Center with fewer risk procedures and fast recovery time.
SMILE procedure, also known as Small Incision Lenticule Extraction, is a laser vision correction for correcting refractive errors and ideal for myopia and other vision problems. It has been prevalent now as the procedure is effective, painless, blade-free, and fast recovery. Baja Eye Center is a reliable place and a NABH accredited for laser eye surgery like Smile for spectacles removal Delhi. With SMILE eye surgery, patients with vision problems could free from their eyeglasses immediately and improve their quality of life.
Bajaj Eye Center was founded by Dr. Rajiv Bajaj in 1996. The clinic has a complete facility and utilizes the most sophisticated technology to diagnose and treat its patients. Before undergoing the SMILE procedure, the patient needs to consult the doctor to ensure their condition and health history. Although SMILE eye surgery is considered safe and quick eye surgery, some conditions are not recommended to take SMILE procedure. They include conditions like suffering from diseases like advanced glaucoma, diabetes, and excessive scarring.
Additionally, people who have eye surgery history, pregnancy, Corneal abrasions, and allergic diseases are not recommended to take the SMILE procedure. Therefore, they need to consult the doctor before taking the procedure. Please call +91-9899072838 or fill the form available at Bajaj Eye Center Contact Us page to make an appointment with a Bajaj Eye Center doctor.
About Bajaj Eye Center
Bajaj Eye Center is a reliable place and registered with the Indian Directorate of Health Services. Bajaj Eye Center is the best place for comprehensive eye surgeries in Delhi, India, due to its sophisticated equipment, experienced surgeon, and friendly staff. Their services include Smile for glass removal in Delhi, Comprehensive eye examination, Diagnostic eye services, Cataract surgery, Retina Services, Oculoplasty Services, Glaucoma services, and more. They aim to provide excellent eye treatment and surgery services with International Standard in Delhi, India.
For more information about Bajaj Eye Center and SMILE eye surgery, please visit http://www.lasikdelhi.com/
Media Contact
Company Name: Bajaj Eye Care Centre
Contact Person: Dr. Rajiv Bajaj
Email: Send Email
Phone: +01147024919
Address:101, Vikas Surya Plaza, Plot No. 7, DDA Community Centre Road No. 44, Pitampura
City: New Delhi
State: Delhi
Country: India
Website: http://www.lasikdelhi.com/
(Added: Tue Mar 30 2021 Hits: 12 Rating: 0.00 Votes: 0) Rate It
- BAJAJ EYE CENTER DELHI IS AVAILABLE FOR AN EYE SURGERY WITH BLADELESS AND PAINLESS PROCEDURE
- Smile eye surgery in Delhi is currently available at the Bajaj eye Center. SMILE Lasik procedure is the most advanced eye surgery for clear vision/enhancing vision. SMILE procedure is better than any eye surgery procedure because it is less invasive than the LASIK procedure. It only takes 2-4 hours of recovery time to return to normal activity. SMILE surgery at Bajaj Eye Center is the third-generation ocular surgery for astigmatism and myopia with many benefits. People with eyesight problems could undergo Smile Lasik in Delhi at Bajaj Eye Center with fewer risk procedures and fast recovery time.
SMILE procedure, also known as Small Incision Lenticule Extraction, is a laser vision correction for correcting refractive errors and ideal for myopia and other vision problems. It has been prevalent now as the procedure is effective, painless, blade-free, and fast recovery. Baja Eye Center is a reliable place and a NABH accredited for laser eye surgery like Smile for spectacles removal Delhi. With SMILE eye surgery, patients with vision problems could free from their eyeglasses immediately and improve their quality of life.
Bajaj Eye Center was founded by Dr. Rajiv Bajaj in 1996. The clinic has a complete facility and utilizes the most sophisticated technology to diagnose and treat its patients. Before undergoing the SMILE procedure, the patient needs to consult the doctor to ensure their condition and health history. Although SMILE eye surgery is considered safe and quick eye surgery, some conditions are not recommended to take SMILE procedure. They include conditions like suffering from diseases like advanced glaucoma, diabetes, and excessive scarring.
Additionally, people who have eye surgery history, pregnancy, Corneal abrasions, and allergic diseases are not recommended to take the SMILE procedure. Therefore, they need to consult the doctor before taking the procedure. Please call +91-9899072838 or fill the form available at Bajaj Eye Center Contact Us page to make an appointment with a Bajaj Eye Center doctor.
About Bajaj Eye Center
Bajaj Eye Center is a reliable place and registered with the Indian Directorate of Health Services. Bajaj Eye Center is the best place for comprehensive eye surgeries in Delhi, India, due to its sophisticated equipment, experienced surgeon, and friendly staff. Their services include Smile for glass removal in Delhi, Comprehensive eye examination, Diagnostic eye services, Cataract surgery, Retina Services, Oculoplasty Services, Glaucoma services, and more. They aim to provide excellent eye treatment and surgery services with International Standard in Delhi, India.
For more information about Bajaj Eye Center and SMILE eye surgery, please visit http://www.lasikdelhi.com/
Media Contact
Company Name: Bajaj Eye Care Centre
Contact Person: Dr. Rajiv Bajaj
Email: Send Email
Phone: +01147024919
Address:101, Vikas Surya Plaza, Plot No. 7, DDA Community Centre Road No. 44, Pitampura
City: New Delhi
State: Delhi
Country: India
Website: http://www.lasikdelhi.com/
(Added: Tue Mar 30 2021 Hits: 9 Rating: 0.00 Votes: 0) Rate It
- BAJAJ EYE CENTER DELHI IS AVAILABLE FOR AN EYE SURGERY WITH BLADELESS AND PAINLESS PROCEDURE
- Smile eye surgery in Delhi is currently available at the Bajaj eye Center. SMILE Lasik procedure is the most advanced eye surgery for clear vision/enhancing vision. SMILE procedure is better than any eye surgery procedure because it is less invasive than the LASIK procedure. It only takes 2-4 hours of recovery time to return to normal activity. SMILE surgery at Bajaj Eye Center is the third-generation ocular surgery for astigmatism and myopia with many benefits. People with eyesight problems could undergo Smile Lasik in Delhi at Bajaj Eye Center with fewer risk procedures and fast recovery time.
SMILE procedure, also known as Small Incision Lenticule Extraction, is a laser vision correction for correcting refractive errors and ideal for myopia and other vision problems. It has been prevalent now as the procedure is effective, painless, blade-free, and fast recovery. Baja Eye Center is a reliable place and a NABH accredited for laser eye surgery like Smile for spectacles removal Delhi. With SMILE eye surgery, patients with vision problems could free from their eyeglasses immediately and improve their quality of life.
Bajaj Eye Center was founded by Dr. Rajiv Bajaj in 1996. The clinic has a complete facility and utilizes the most sophisticated technology to diagnose and treat its patients. Before undergoing the SMILE procedure, the patient needs to consult the doctor to ensure their condition and health history. Although SMILE eye surgery is considered safe and quick eye surgery, some conditions are not recommended to take SMILE procedure. They include conditions like suffering from diseases like advanced glaucoma, diabetes, and excessive scarring.
Additionally, people who have eye surgery history, pregnancy, Corneal abrasions, and allergic diseases are not recommended to take the SMILE procedure. Therefore, they need to consult the doctor before taking the procedure. Please call +91-9899072838 or fill the form available at Bajaj Eye Center Contact Us page to make an appointment with a Bajaj Eye Center doctor.
About Bajaj Eye Center
Bajaj Eye Center is a reliable place and registered with the Indian Directorate of Health Services. Bajaj Eye Center is the best place for comprehensive eye surgeries in Delhi, India, due to its sophisticated equipment, experienced surgeon, and friendly staff. Their services include Smile for glass removal in Delhi, Comprehensive eye examination, Diagnostic eye services, Cataract surgery, Retina Services, Oculoplasty Services, Glaucoma services, and more. They aim to provide excellent eye treatment and surgery services with International Standard in Delhi, India.
For more information about Bajaj Eye Center and SMILE eye surgery, please visit http://www.lasikdelhi.com/
Media Contact
Company Name: Bajaj Eye Care Centre
Contact Person: Dr. Rajiv Bajaj
Email: Send Email
Phone: +01147024919
Address:101, Vikas Surya Plaza, Plot No. 7, DDA Community Centre Road No. 44, Pitampura
City: New Delhi
State: Delhi
Country: India
Website: http://www.lasikdelhi.com/
(Added: Tue Mar 30 2021 Hits: 16 Rating: 0.00 Votes: 0) Rate It
- BAJAJ EYE CENTER DELHI IS AVAILABLE FOR AN EYE SURGERY WITH BLADELESS AND PAINLESS PROCEDURE
- Smile eye surgery in Delhi is currently available at the Bajaj eye Center. SMILE Lasik procedure is the most advanced eye surgery for clear vision/enhancing vision. SMILE procedure is better than any eye surgery procedure because it is less invasive than the LASIK procedure. It only takes 2-4 hours of recovery time to return to normal activity. SMILE surgery at Bajaj Eye Center is the third-generation ocular surgery for astigmatism and myopia with many benefits. People with eyesight problems could undergo Smile Lasik in Delhi at Bajaj Eye Center with fewer risk procedures and fast recovery time.
SMILE procedure, also known as Small Incision Lenticule Extraction, is a laser vision correction for correcting refractive errors and ideal for myopia and other vision problems. It has been prevalent now as the procedure is effective, painless, blade-free, and fast recovery. Baja Eye Center is a reliable place and a NABH accredited for laser eye surgery like Smile for spectacles removal Delhi. With SMILE eye surgery, patients with vision problems could free from their eyeglasses immediately and improve their quality of life.
Bajaj Eye Center was founded by Dr. Rajiv Bajaj in 1996. The clinic has a complete facility and utilizes the most sophisticated technology to diagnose and treat its patients. Before undergoing the SMILE procedure, the patient needs to consult the doctor to ensure their condition and health history. Although SMILE eye surgery is considered safe and quick eye surgery, some conditions are not recommended to take SMILE procedure. They include conditions like suffering from diseases like advanced glaucoma, diabetes, and excessive scarring.
Additionally, people who have eye surgery history, pregnancy, Corneal abrasions, and allergic diseases are not recommended to take the SMILE procedure. Therefore, they need to consult the doctor before taking the procedure. Please call +91-9899072838 or fill the form available at Bajaj Eye Center Contact Us page to make an appointment with a Bajaj Eye Center doctor.
About Bajaj Eye Center
Bajaj Eye Center is a reliable place and registered with the Indian Directorate of Health Services. Bajaj Eye Center is the best place for comprehensive eye surgeries in Delhi, India, due to its sophisticated equipment, experienced surgeon, and friendly staff. Their services include Smile for glass removal in Delhi, Comprehensive eye examination, Diagnostic eye services, Cataract surgery, Retina Services, Oculoplasty Services, Glaucoma services, and more. They aim to provide excellent eye treatment and surgery services with International Standard in Delhi, India.
For more information about Bajaj Eye Center and SMILE eye surgery, please visit http://www.lasikdelhi.com/
Media Contact
Company Name: Bajaj Eye Care Centre
Contact Person: Dr. Rajiv Bajaj
Email: Send Email
Phone: +01147024919
Address:101, Vikas Surya Plaza, Plot No. 7, DDA Community Centre Road No. 44, Pitampura
City: New Delhi
State: Delhi
Country: India
Website: http://www.lasikdelhi.com/
(Added: Tue Mar 30 2021 Hits: 8 Rating: 0.00 Votes: 0) Rate It
- Medical Mask N95
- Medical Mask N95 is a Chinese standard mask.Medical mask N95 is a type of masks with particulate filtering efficiency in our country.
Medical mask N95 and KN95 masks are actually the same in terms of particulate filtering efficiency. KN95 is a Chinese standard mask. N95 is an American standard.
The N95 mask is one of nine particulate protective masks certified by NIOSH (National Institute for Occupational Safety and Health). N95 is not a specific product name. As long as it meets the N95 standard and passed the NIOSH review, it can be called a N95 mask, which can filter particles with an aerodynamic diameter of 0.075µm ± 0.020µm and achieve an efficiency of more than 95%.
(Added: Mon Mar 29 2021 Hits: 5 Rating: 0.00 Votes: 0) Rate It
- Webinar On Respiratory Disorder and Therapy
- Meetings International is hosting the webinar on Respiratory Care 2021 is scheduled for April 30; 2021The primary topic of the Respiratory Care 2021 is "Current Challenges and Innovative Therapeutics in Respiratory care".
(Added: Mon Mar 29 2021 Hits: 6 Rating: 0.00 Votes: 0) Rate It
- International Conference On Transplantation
- Inviting all the participants over the earth to take part in International Conference on Transplantation 2021 to be held during Dec 08-09, 2021, which cover prompt keynote presentations, Oral talks, Poster presentations, and Exhibitions.
Transplantation conference 2021 which organizes 1000+ Global events regularly is glad to welcome all the interested and enthusiastic participants across the sphere to its prestigious Conference on Transplantation which goes to be held in Dubai, UAE
(Added: Mon Mar 29 2021 Hits: 8 Rating: 0.00 Votes: 0) Rate It
- Thelansis Crohn’s Disease (CD) Market Outlook and Competitive Landscape Report 2015 - 2030
- Thelansis Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two diseases are very similar, so it is sometimes difficult to establish a definitive diagnosis. One difference, however, is that ulcerative colitis affects only the colon, while Crohn’s disease may affect any part of the GI tract and often affects the end of the small bowel (the ileum) and the beginning of the colon.
Thelansis "Crohn’s disease (CD) – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape. Half of all CD cases involve the ileum and colon and in 25% of cases, only the colon is affected. Approximately 15% of colitis cases are called indeterminate colitis because they cannot be classified as either ulcerative colitis or Crohn’s disease.
Market landscape:
According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$5,425 MN in 2015 and expected to reach at ~$ 12,346 MN by the end of 2030 (15 years of markets projections; four years of historical data, current and eleven years of future market projections). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
A population-based study the total number of new cases of Crohn’s disease diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 34,976 new cases per year, however, the number of new cases of ulcerative colitis diagnosed each year was ~41,250 new cases per year
Epidemiology and patient segmentation:
According to Thelansis, globally ~ 2.3 MN patients are being diagnosed with Crohn’s disease (CD) in 2015 among which 8MM countries are comprised of ~75% of the total yearly reported cases. The total current market of Crohn’s disease is $ 3,821 MN in 2015 and expected to reach at ~$ 12,049 MN by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease
Crohn’s disease - biomarker level patient segmentation:
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)
Current therapy:
One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.
There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA)
• Corticosteroids
• Antibiotics
• Immune modifiers
• Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.)
• Others
As many as 75% of Crohn’s disease patients required at least one surgical procedure during their lives, most often due to lack of response to medical therapy. Additional indications for surgery include intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. The overall goal of surgery in Crohn’s disease is to conserve bowel function and return the individual to the best possible quality of life. Continued use of medications is necessary to minimize the risk of recurrences.
Emerging therapies:
As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS
The annual cost of therapy:
According to the published literature review, Crohn’s disease is one of the most prevalent diseases in the United States including other developed and developing nations. For patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization cost.
Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively
KOL’s Perspective:
Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with moderate to severe stage of Crohn’s disease currently on biologics or any other form of targeted therapy
More than 55% of the disease population diagnosed in their later stage of the disease, so the awareness around diagnosis procedure and technology need to be spread around to maximize the early diagnosis
Multiple targets need to be identified and targeted to get control on the quality of life of the patients
Payer’s perspective:
From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce Crohn’s disease-related expenditures. The treatment of Crohn’s disease has changed dramatically since the launch of biosimilars of many TNF alpha biologics. Screening has and will continue to increase cure rates. Molecular profiling, coupled with biosimilars version of targeted therapies and the expanding role of immunotherapy, is becoming so effective and justifiably that the cost saving has been going up at each passing day.
The European nations regulatory bodies and payers are having a very positive mindset with respect to the approval and access of biosimilars, which will bring the country level disease burden as well as the treatment cost in coming years. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients.
About the company
As the name depicts Thelansis is specialized in “Therapy Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, clientsupport@thelansis.com
Sales office:
Thelansis Knowledge Partners
https://thelansis.com
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552
Delivery Office:
Thelansis Knowledge Partners
B-1030,
C Wing Vrindavan tech village
Marathahalli Outer ring road
Bangalore- 560037
India
Mob.: +91-9899921259
sales@thelansis.com,
clientsupport@thelansis.com
(Added: Sat Mar 27 2021 Hits: 16 Rating: 0.00 Votes: 0) Rate It
- Thelansis Crohn’s Disease Market Outlook and Competitive Landscape Report 2015 - 2030
- Thelansis Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two diseases are very similar, so it is sometimes difficult to establish a definitive diagnosis. One difference, however, is that ulcerative colitis affects only the colon, while Crohn’s disease may affect any part of the GI tract and often affects the end of the small bowel (the ileum) and the beginning of the colon.
Thelansis "Crohn’s disease (CD) – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape. Half of all CD cases involve the ileum and colon and in 25% of cases, only the colon is affected. Approximately 15% of colitis cases are called indeterminate colitis because they cannot be classified as either ulcerative colitis or Crohn’s disease.
Market landscape:
According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$5,425 MN in 2015 and expected to reach at ~$ 12,346 MN by the end of 2030 (15 years of markets projections; four years of historical data, current and eleven years of future market projections). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
A population-based study the total number of new cases of Crohn’s disease diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 34,976 new cases per year, however, the number of new cases of ulcerative colitis diagnosed each year was ~41,250 new cases per year
Epidemiology and patient segmentation:
According to Thelansis, globally ~ 2.3 MN patients are being diagnosed with Crohn’s disease (CD) in 2015 among which 8MM countries are comprised of ~75% of the total yearly reported cases. The total current market of Crohn’s disease is $ 3,821 MN in 2015 and expected to reach at ~$ 12,049 MN by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease
Crohn’s disease - biomarker level patient segmentation:
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)
Current therapy:
One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.
There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA)
• Corticosteroids
• Antibiotics
• Immune modifiers
• Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.)
• Others
As many as 75% of Crohn’s disease patients required at least one surgical procedure during their lives, most often due to lack of response to medical therapy. Additional indications for surgery include intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. The overall goal of surgery in Crohn’s disease is to conserve bowel function and return the individual to the best possible quality of life. Continued use of medications is necessary to minimize the risk of recurrences.
Emerging therapies:
As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS
The annual cost of therapy:
According to the published literature review, Crohn’s disease is one of the most prevalent diseases in the United States including other developed and developing nations. For patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization cost.
Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively
KOL’s Perspective:
Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with moderate to severe stage of Crohn’s disease currently on biologics or any other form of targeted therapy
More than 55% of the disease population diagnosed in their later stage of the disease, so the awareness around diagnosis procedure and technology need to be spread around to maximize the early diagnosis
Multiple targets need to be identified and targeted to get control on the quality of life of the patients
Payer’s perspective:
From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce Crohn’s disease-related expenditures. The treatment of Crohn’s disease has changed dramatically since the launch of biosimilars of many TNF alpha biologics. Screening has and will continue to increase cure rates. Molecular profiling, coupled with biosimilars version of targeted therapies and the expanding role of immunotherapy, is becoming so effective and justifiably that the cost saving has been going up at each passing day.
The European nations regulatory bodies and payers are having a very positive mindset with respect to the approval and access of biosimilars, which will bring the country level disease burden as well as the treatment cost in coming years. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients.
About the company
As the name depicts Thelansis is specialized in “Therapy Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, clientsupport@thelansis.com
Sales office:
Thelansis Knowledge Partners
https://thelansis.com
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552
Delivery Office:
Thelansis Knowledge Partners
B-1030,
C Wing Vrindavan tech village
Marathahalli Outer ring road
Bangalore- 560037
India
Mob.: +91-9899921259
sales@thelansis.com,
clientsupport@thelansis.com
(Added: Sat Mar 27 2021 Hits: 10 Rating: 0.00 Votes: 0) Rate It
- Thelansis Crohn’s Disease Market Outlook and Competitive Landscape Report 2015 - 2030
- Thelansis Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two diseases are very similar, so it is sometimes difficult to establish a definitive diagnosis. One difference, however, is that ulcerative colitis affects only the colon, while Crohn’s disease may affect any part of the GI tract and often affects the end of the small bowel (the ileum) and the beginning of the colon.
Thelansis "Crohn’s disease (CD) – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape. Half of all CD cases involve the ileum and colon and in 25% of cases, only the colon is affected. Approximately 15% of colitis cases are called indeterminate colitis because they cannot be classified as either ulcerative colitis or Crohn’s disease.
Market landscape:
According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$5,425 MN in 2015 and expected to reach at ~$ 12,346 MN by the end of 2030 (15 years of markets projections; four years of historical data, current and eleven years of future market projections). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
A population-based study the total number of new cases of Crohn’s disease diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 34,976 new cases per year, however, the number of new cases of ulcerative colitis diagnosed each year was ~41,250 new cases per year
Epidemiology and patient segmentation:
According to Thelansis, globally ~ 2.3 MN patients are being diagnosed with Crohn’s disease (CD) in 2015 among which 8MM countries are comprised of ~75% of the total yearly reported cases. The total current market of Crohn’s disease is $ 3,821 MN in 2015 and expected to reach at ~$ 12,049 MN by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease
Crohn’s disease - biomarker level patient segmentation:
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)
Current therapy:
One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.
There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA)
• Corticosteroids
• Antibiotics
• Immune modifiers
• Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.)
• Others
As many as 75% of Crohn’s disease patients required at least one surgical procedure during their lives, most often due to lack of response to medical therapy. Additional indications for surgery include intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. The overall goal of surgery in Crohn’s disease is to conserve bowel function and return the individual to the best possible quality of life. Continued use of medications is necessary to minimize the risk of recurrences.
Emerging therapies:
As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS
The annual cost of therapy:
According to the published literature review, Crohn’s disease is one of the most prevalent diseases in the United States including other developed and developing nations. For patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization cost.
Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively
KOL’s Perspective:
Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with moderate to severe stage of Crohn’s disease currently on biologics or any other form of targeted therapy
More than 55% of the disease population diagnosed in their later stage of the disease, so the awareness around diagnosis procedure and technology need to be spread around to maximize the early diagnosis
Multiple targets need to be identified and targeted to get control on the quality of life of the patients
Payer’s perspective:
From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce Crohn’s disease-related expenditures. The treatment of Crohn’s disease has changed dramatically since the launch of biosimilars of many TNF alpha biologics. Screening has and will continue to increase cure rates. Molecular profiling, coupled with biosimilars version of targeted therapies and the expanding role of immunotherapy, is becoming so effective and justifiably that the cost saving has been going up at each passing day.
The European nations regulatory bodies and payers are having a very positive mindset with respect to the approval and access of biosimilars, which will bring the country level disease burden as well as the treatment cost in coming years. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients.
About the company
As the name depicts Thelansis is specialized in “Therapy Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, clientsupport@thelansis.com
Sales office:
Thelansis Knowledge Partners
https://thelansis.com
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552
Delivery Office:
Thelansis Knowledge Partners
B-1030,
C Wing Vrindavan tech village
Marathahalli Outer ring road
Bangalore- 560037
India
Mob.: +91-9899921259
sales@thelansis.com,
clientsupport@thelansis.com
(Added: Sat Mar 27 2021 Hits: 6 Rating: 0.00 Votes: 0) Rate It
- Thelansis Crohn’s Disease Market Outlook and Competitive Landscape Report 2015 - 2030
- Thelansis Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two diseases are very similar, so it is sometimes difficult to establish a definitive diagnosis. One difference, however, is that ulcerative colitis affects only the colon, while Crohn’s disease may affect any part of the GI tract and often affects the end of the small bowel (the ileum) and the beginning of the colon.
Thelansis "Crohn’s disease (CD) – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape. Half of all CD cases involve the ileum and colon and in 25% of cases, only the colon is affected. Approximately 15% of colitis cases are called indeterminate colitis because they cannot be classified as either ulcerative colitis or Crohn’s disease.
Market landscape:
According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$5,425 MN in 2015 and expected to reach at ~$ 12,346 MN by the end of 2030 (15 years of markets projections; four years of historical data, current and eleven years of future market projections). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
A population-based study the total number of new cases of Crohn’s disease diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 34,976 new cases per year, however, the number of new cases of ulcerative colitis diagnosed each year was ~41,250 new cases per year
Epidemiology and patient segmentation:
According to Thelansis, globally ~ 2.3 MN patients are being diagnosed with Crohn’s disease (CD) in 2015 among which 8MM countries are comprised of ~75% of the total yearly reported cases. The total current market of Crohn’s disease is $ 3,821 MN in 2015 and expected to reach at ~$ 12,049 MN by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease
Crohn’s disease - biomarker level patient segmentation:
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)
Current therapy:
One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.
There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA)
• Corticosteroids
• Antibiotics
• Immune modifiers
• Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.)
• Others
As many as 75% of Crohn’s disease patients required at least one surgical procedure during their lives, most often due to lack of response to medical therapy. Additional indications for surgery include intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. The overall goal of surgery in Crohn’s disease is to conserve bowel function and return the individual to the best possible quality of life. Continued use of medications is necessary to minimize the risk of recurrences.
Emerging therapies:
As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS
The annual cost of therapy:
According to the published literature review, Crohn’s disease is one of the most prevalent diseases in the United States including other developed and developing nations. For patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization cost.
Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively
KOL’s Perspective:
Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with moderate to severe stage of Crohn’s disease currently on biologics or any other form of targeted therapy
More than 55% of the disease population diagnosed in their later stage of the disease, so the awareness around diagnosis procedure and technology need to be spread around to maximize the early diagnosis
Multiple targets need to be identified and targeted to get control on the quality of life of the patients
Payer’s perspective:
From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce Crohn’s disease-related expenditures. The treatment of Crohn’s disease has changed dramatically since the launch of biosimilars of many TNF alpha biologics. Screening has and will continue to increase cure rates. Molecular profiling, coupled with biosimilars version of targeted therapies and the expanding role of immunotherapy, is becoming so effective and justifiably that the cost saving has been going up at each passing day.
The European nations regulatory bodies and payers are having a very positive mindset with respect to the approval and access of biosimilars, which will bring the country level disease burden as well as the treatment cost in coming years. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients.
About the company
As the name depicts Thelansis is specialized in “Therapy Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, clientsupport@thelansis.com
Sales office:
Thelansis Knowledge Partners
https://thelansis.com
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552
Delivery Office:
Thelansis Knowledge Partners
B-1030,
C Wing Vrindavan tech village
Marathahalli Outer ring road
Bangalore- 560037
India
Mob.: +91-9899921259
sales@thelansis.com,
clientsupport@thelansis.com
(Added: Sat Mar 27 2021 Hits: 11 Rating: 0.00 Votes: 0) Rate It
- Church of Scientology Nashville Continues to Encourage Safety Measures Against COVID-19
- The Churches of Scientology Disaster Response are known for helping communities during times of emergency.
Senior members of the White House COVID-19 Response Team are concerned that state governments are relaxing pandemic restrictions too early, as vaccine rollouts race against rapidly spreading coronavirus variants. It is with this in mind that the Nashville Church of Scientology Volunteer Ministers are encouraging friends and neighbors to keep in safety protocols such as wearing a face mask and gloves when outside the home.
The Church of Scientology’s Volunteer Ministers have taken part in an initiative designed to keep communities safe while cities and states reopen. They distributed over 15,000 “Stay Well” booklets to local stores, restaurants, grocery stores, clinics, hospitals and homes in the Nashville area.
Based on the principle that an ounce of prevention is worth a ton of cure, they dressed in their signature yellow jackets and caps and additional protective gear and loaded up with sets of three booklets: How to Keep Yourself & Others Well, How to Protect Yourself & Others with a Mask & Gloves and How to Prevent the Spread of Illness with Isolation.
Scientology Volunteer Ministers are making these booklets available across Nashville, and in communities around the world in 21 languages. They are even downloadable from scientology.org/staywell.
Nashville and Tennessee were not the worst hit by the pandemic, but still have had more than 790,000 cases in Tennessee, and 90,000 in the Nashville area and counting. “We’ve stepped up to take this pandemic down,” said one of the Volunteer Ministers. “People have been so grateful for the booklets.”
Each booklet has a QR code on the back that goes to the How to Stay Well Prevention Center on the Scientology website, which makes these and other prevention materials available, free of charge. The booklets can be read on the website or downloaded. More than a dozen brief videos illustrate the key information, making it easy to understand what a virus is, how it spreads, and the actions anyone can take to protect themselves and their families.
Worldwide distribution of these booklets began in May 2020 in communities around Scientology Churches and Missions across the globe. The Church of Scientology International Dissemination and Distribution Center made this possible by printing and shipping 5 million copies of Stay Well booklets.
The Church of Scientology Volunteer Ministers program is a religious social service created in the mid-1970s by Scientology Founder L. Ron Hubbard. It constitutes one of the largest and most visible international independent relief forces. The Volunteer Minister’s mandate is to be “a person who helps his fellow man on a volunteer basis by restoring purpose, truth and spiritual values to the lives of others.”
For more information or to learn more, visit Scientology.org/StayWell.
(Added: Thu Mar 25 2021 Hits: 7 Rating: 0.00 Votes: 0) Rate It
- Drug-Free Tennessee Plans Virtual Awareness Campaign for World Health Day 2021
- Drug-Free Tennessee is planning a virtual awareness campaign for World Health Day this April 2021.
In past years, Drug-Free Tennessee (DFT) has focused a World Health Day event around different topics with one standing out above others: Shape Up and Be Happy. This has long been the group’s campaign for the Day with organizations participating to help residents get into a healthy mindset each April.
DFT works closely with the Church of Scientology Nashville to host these events each year. The 2020 event was naturally canceled due to COVID-19, and for 2021, the group plans to take it virtual, sharing resources all day on April 7th.
Drug-Free Tennessee provides education on the truth about drugs, which is of course its mission, and ties right into healthy living. Spokesperson for the group, Julie Brinker said, “You can’t have overall health and wellness with harmful street drugs in your system, and Drug-Free Tennessee is working hard to spread that message around the state.” Other educational initiatives for a healthy lifestyle will be shared virtually as well, including tips for eating and exercising.
This is the sixth year Drug-Free Tennessee (DFT) has worked with the community to celebrate World Health Day. DFT is a chapter of the Foundation for a Drug-Free World (FDFW), which has as its mission to educate people about the dangerous effects of drugs so they understand and can make informed choices on the subject. The Tennessee chapter provides educational materials free of charge to anyone working on drug prevention, and observes World Health Day as a vital point of awareness on the hazards of illegal and dangerous drugs.
For more information on the Drug-Free Tennessee, visit drugfreetn.org. For more on the Church of Scientology or its programs, visit scientology-ccnashville.org.
(Added: Thu Mar 25 2021 Hits: 9 Rating: 0.00 Votes: 0) Rate It
Pages: [<<] ... 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 ... [>>]
Links SQL By: Gossamer Threads Inc.
